Insurance
Latest News
Can Medicare Sustain Widespread Access to GLP-1 Therapies?
April 25th 2025
Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related health issues, but it also risks adding tens of billions in new costs, highlighting the need for smart policy strategies to ensure access, affordability, and long-term sustainability.
